32 results about "Coronary artery stent" patented technology

A coated implantable medical device 10 includes a structure 12 adapted for introduction into the vascular system, esophagus, trachea, colon, biliary tract, or urinary tract; at least one coating layer 16 posited on one surface of the structure; and at least one layer 18 of a bioactive material posited on at least a portion of the coating layer 16, wherein the coating layer 16 provides for the controlled release of the bioactive material from the coating layer. In addition, at least one porous layer 20 can be posited over the bioactive material layer 18, wherein the porous layer includes a polymer and provides for the controlled release of the bioactive material therethrough. Preferably, the structure 12 is a coronary stent. The porous layer 20 includes a polymer applied preferably by vapor or plasma deposition and provides for a controlled release of the bioactive material. It is particularly preferred that the polymer is a polyamide, parylene or a parylene derivative, which is deposited without solvents, heat or catalysts, and merely by condensation of a monomer vapor.

The invention relates to the field of coronary stents, specifically to a method for reducing the incidence of in-stent restenosis and its special stainless steel material. The method of the invention adds a proper amount of copper element (2.0-6.0% by weight) into the common clinical coronary stent material 316L stainless steel, and conducts special heat treatment so as to make the copper separated in a copper-rich phase out of the stainless steel substrate. The stent is enabled to continuously release trace amounts of copper ions in a clinical environment, and the coronary stent is endowed with an anti-restenotic function, thus effectively reducing the incidence of restenosis after stent implantation. With a unique function of reducing the in-stent restenosis phenomenon caused by stent implantation into a coronary artery, the 316L type copper-containing stainless steel of the invention is conducive to solve clinical problems such as high incidence of in-stent restenosis after implantation of existing stainless steel coronary stents, and can be applied in coronary stents and other clinical medicine fields, thus providing a new idea and material basis for development and application of coronary stents.

The invention discloses a medicament for preventing in-stent restenosis after coronary stent implantation and a preparation method. The medicament is prepared into 1000 parts from, by weight, 800-1200 parts of tanshinone, 200-300 parts of hirudin, 20-30 parts of camphol and borneol and 6-9 parts of musk ketone. The medicament has the advantages of effective treatment, no toxic and side effects and capabilities of decreasing occurrence rate of in-stent restenosis after coronary stent implantation, obviously improving clinical symptoms of patients and reducing long-term risks of thrombosis of the patients, and is obvious in clinical effect. The medicament provides a new choice for preventing ISR (in-stent restenosis) after coronary stent implantation.

An assembly and planar structure for use therein which is expandable into a 3-D structure such as a stent and device for making the planar structure are provided. The planar structure permits the use of planar batch manufacturing technologies to fabricate coronary artery stents. Stents with different wall patterns are fabricated from 50 μm thick stainless steel foil using micro-electro-discharge machining, and expanded to tubular shapes by using angioplasty balloons. The stents are free-standing. The free-standing stents exhibit diameter variations of <±4%, almost zero radial recoil after deflation of the balloon, and longitudinal shrinkage of <3% upon expansion. A variation of the stents uses breakable links to provide additional customization of electrical and mechanical properties. Loading tests reveal that the radial strengths match commercially available stents, while longitudinal compliance, at 0.02 m / N for a 4 mm long section of the stent, is substantially higher.

The invention discloses a method for manufacturing a heart structure by using a rollover process of a 3D printing technology, and aims to solve the problems that only the internal structure of the heart can be displayed and a later heart model rollover technology is lacked in the prior art, so that a heart practice medical teaching aid is manufactured to meet various surgical operations of the internal structure of the heart and coronary artery stent and bridging technology practice; and human heart structure real data are obtained through heart structure medical imaging and data digitization, heart three-dimensional data structure data are subjected to 3D printing to manufacture a heart model or a heart template, the toughness and thickness of heart valves and the shape and thickness of coronary arteries are achieved. According to the heart silica gel filling, all reserved template gaps can be uniformly filled through negative pressure attraction silica gel according to product requirements, compared with a traditional manufacturing method, the rate of finished products is high, and the internal structure shape of the heart is closer to the real heart structure of a human body; and the artificial heart can be used for simulating and practicing clinical operation skills such as heart cutting, sewing, plugging, coronary artery stenting and bridging.

The invention discloses a cutting process of a coronary artery stent. A specific operation method comprises the following steps: pre-treating a plurality of stent patterns which are the same or have different specifications respectively; carrying out staggered placement on the tail end of a first stent pattern and the front end of a second stent pattern, so as to move the tail end of the first stent pattern into remains, which do not need to be machined, in the front end of the second stent pattern in a staggered manner; reserving process allowance in a laser cutting process, and so on, and placing the third or more stent patterns; generating an NC procedure on host equipment through the plurality of patterns which are arranged in the staggered manner, and cutting a stent pipe through a laser cutting machine; cutting off the process allowance to separate the coronary artery stents. According to the cutting process of the coronary artery stent, the plurality of stent patterns are arranged in the staggered manner and then are machined as a whole body, so that the production efficiency is remarkably improved and the utilization rate of the pipe is greatly improved, and furthermore, a lot of raw materials are saved.

The invention provides a restenosis monitoring device and method based on an intelligent coronary stent. The device comprises a first blood state detection device, a second blood state detection device, a third blood state detection device and an external data processing device; wherein each blood state detection device comprises: a sensor group, an internal processor, an energy supply device anda radio frequency emission module; the external data processing device comprises a radio frequency receiving module, a memory and a data processor; the radio frequency receiving module is used for receiving an electric signal from the radio frequency emission modules, the memory is used for storing the electric signal, and the data processor periodically retrieves the electric signal from the memory; when the value of a blood state function G is within a judgment interval [delta]Sn, the external data processing device does not work; and when the value of the blood state function G is outside the judgment interval [delta]Sn, the external data processing device simultaneously sends an alarm notification to a patient and a hospital.

The invention provides a cobalt-based alloy. The cobalt-based alloy includes Cu element, wherein the content of Cu element is 4.5-5.5% by weight. The invention also provides a thermal processing method and a heat treatment method of the cobalt-based alloy; and the application of the cobalt-based alloy as a coronary artery stent. The cobalt-based alloy continuously produces trace amounts of copper in the cardiovascular system, which can not only inhibit the hyperplasia, migration and degeneration of arterial smooth muscle after coronary stent implantation, but also effectively reduce the formation of thrombus, thereby reducing or inhibiting coronary artery stent implantation. Function of in-stent restenosis induced after implantation.

The invention is intended for use in medicine and enables maximally precise, quick and safe positioning of a coronary stent in the case of uncomplicated and complicated anatomical injuries of the coronary vascular bed, and also when stenting renal and visceral arteries. The claimed device consists of a body with a tail portion, a wheel for rotating a screw, a screw, a slider with threaded elementsand a scale for identifying the position of the slider and a resilient tensioning member with elastic locking members disposed thereon, a wedge piece consisting of two elements, a spring and a lock button, arranged inside the body. When preparing the device for use, the coronary stent is first inserted on a delivery system into the device; the coronary stent is then manually manoeuvred on the delivery system to the injured site of the coronary artery, the delivery system is locked in the device, and the stent is positioned in the coronary artery using the rotation wheel. A second embodiment of the device consists of a body with a tail portion, a wheel for rotating a screw, a screw, rotating gears, a clamping cylinder, and a lock button with springs for accommodating guides for a deliverysystem inside the body. When preparing the device for use, the coronary stent is first inserted on a delivery system into the device; the coronary stent is then manually manoeuvred on the delivery system to the injured site of the coronary artery, the delivery system is locked in the device, and the stent is positioned in the coronary artery using the rotation wheel.

The present invention relates to D-galactopyranose compounds of formula (1) wherein the pyranose ring is beta-D-galactopyranose, these compounds are high affinity galectin-1 and / or-3 inhibitors for use in the treatment of inflammation; thrombosis caused by inflammation; specific dermatitis; acute coronary syndrome; fibrosis, such as pulmonary fibrosis, hepatic fibrosis, renal fibrosis, ocular fibrosis, and fibrosis of the skin and heart; local fibrosis, such as Duput's foot disease and Petroleum disease; fibrosis complications of other therapies such as coronary artery stents, bile duct stents, cerebral artery stents and ureteral stents; scleroderma; scars; scar tumor formation; new coronal pneumonia-19; acute lung injury; an ARDS; viral pneumonia; abnormal scar formation; surgical adhesion; infectious shock; cancers such as colorectal cancer, other gastrointestinal cancers such as pancreatic cancer, gastric cancer, biliary tract cancer, lung cancer, mesothelioma, female cancers such as breast cancer, ovarian cancer, uterine cancer, cervical cancer, fallopian tube cancer, brain cancers such as myeloblastoma, glioma, meningioma, skeletal and muscle sarcoma and other sarcoma, leukemia and lymphoma such as T cell lymphoma; transplant rejection; metastatic cancers; aging; dementia; alzheimer's disease; bone diseases driven by TGF-beta, such as osteogenesis imperfection; pulmonary arterial hypertension; autoimmune diseases, such as psoriasis, rheumatoid arthritis, rheumatoid lung disease; , Crohn's disease, ulcerative colitis, ankylosing spondylitis, systemic lupus erythematosus; viral infections such as influenza virus, HIV, herpes virus, coronavirus, hepatitis C; metabolic disorders; heart diseases; heart failure; pathological angiogenesis, such as ocular angiogenesis or a disease or condition associated with ocular angiogenesis, such as cancer-associated neovascularization; and ocular diseases such as age-related macular degeneration and corneal neovascularization; atherosclerosis; metabolic diseases; diabetes; type I diabetes; type 2 diabetes; insulin resistance; obesity; marfan's syndrome; a Royal's syndrome; kidney disease; diastolic heart failure; fibrotic pulmonary complications of aPD1 and other CPI therapies; asthma and other interstitial lung diseases, including Hermanski-Priderac syndrome, liver diseases, such as non-alcoholic steatohepatitis or non-alcoholic fatty liver disease; uterine diseases, such as uterine fibroids and uterine or cervical fibrosis.

The invention relates to a precise positioning system for a coronary artery opening stent. The system comprises a guide wire, a stent and a stent conveying device for conveying the stent, wherein the stent conveying device comprises a shaft tube, a pre-expanded balloon arranged at the front end of the shaft tube and a positioning balloon positioned at the back end of the pre-expanded balloon; a valve is arranged at the expanding cavity position between the positioning balloon and the pre-expanded balloon; when relatively low pressure is applied, the positioning balloon expands firstly to perform positioning; and pressure is applied continuously, the valve is opened and the pre-expanded balloon is expanded, so that the stent is implanted.

The invention relates to a forming technology of superfine thin walled tubular products for vessel stents in the field of treatment, specifically to a method of processing cobalt-base alloy superfine thin walled tubes for novel coronary artery stents. The method solves the problems of great difficulty in tubular product processing and low yield of tubular products in a conventional technology. The method for forming finished products comprises the successive technological processes of smelting, forging, hot rolling, hot rolling punching, honing and cleaning of inner surfaces and outer surfaces, annealing, cold rolling / drawing, annealing, and repeated cold rolling / drawing. During overall process of the repeated cold rolling, diameter reducing deformation of the tubular products should be controlled in each pass, and match relationship between the diameter reducing deformation and wall reducing deformation should be well adjusted for guaranteeing that load carrying capability of inner walls does not exceed sigma b (breaking strength) and thus for preventing horizontal microscopic breakage. With rough blanks of the tubular products being acquired in high temperature conditions and the cobalt-base alloy tubular products being acquired through rolling at a room temperature, the processing method guarantees high dimensional precision, bright and clean inner and outer surfaces and excellent mechanical property of the tubular products; and is easy to realize and has high controllability and high economic benefit.

The present invention relates to D-galactopyranose compounds of formula (1) wherein the pyranose ring is beta-D-galactopyranose, these compounds are high affinity galectin-3 inhibitors for use in the treatment of inflammation; thrombosis caused by inflammation; specific dermatitis; acute coronary syndrome; fibrosis, such as pulmonary fibrosis, hepatic fibrosis, renal fibrosis, ocular fibrosis, and fibrosis of the skin and heart; local fibrosis, such as Duput's foot disease and Petroleum disease; fibrosis complications of other therapies such as coronary artery stents, bile duct stents, cerebral artery stents and ureteral stents; scleroderma; scars; scar tumor formation; new coronal pneumonia-19; acute lung injury; an ARDS; viral pneumonia; abnormal scar formation; surgical adhesion; infectious shock; cancers such as colorectal cancer, other gastrointestinal cancers such as pancreatic cancer, gastric cancer, biliary tract cancer, lung cancer, mesothelioma, female cancers such as breast cancer, ovarian cancer, uterine cancer, cervical cancer, fallopian tube cancer, brain cancers such as myeloblastoma, glioma, meningioma, skeletal and muscle sarcoma and other sarcoma, leukemia and lymphoma such as T cell lymphoma; transplant rejection; metastatic cancers; aging; dementia; alzheimer's disease; bone diseases driven by TGF-beta, such as osteogenesis imperfection; pulmonary arterial hypertension; autoimmune diseases, such as psoriasis, rheumatoid arthritis, rheumatoid lung disease; , Crohn's disease, ulcerative colitis, ankylosing spondylitis, systemic lupus erythematosus; viral infections such as influenza virus, HIV, herpes virus, coronavirus, hepatitis C; metabolic disorders; heart diseases; heart failure; pathological angiogenesis, such as ocular angiogenesis or a disease or condition associated with ocular angiogenesis, such as neovascularization associated with cancer; and ocular diseases such as age-related macular degeneration and corneal neovascularization; atherosclerosis; metabolic diseases; diabetes; type I diabetes; type 2 diabetes; insulin resistance; obesity; marfan's syndrome; a Royal's syndrome; kidney disease; diastolic heart failure; fibrotic pulmonary complications of aPD1 and other CPI therapies; asthma and other interstitial lung diseases, including Hermanski-Priderac syndrome, liver diseases, such as non-alcoholic steatohepatitis or non-alcoholic fatty liver disease; uterine diseases, such as uterine fibroids and uterine or cervical fibrosis.

The invention relates to an operating platform for percutaneous coronary artery stent implantation, which consists of a tainted blood tank, a cotton gauze tank, a sundries tank, a near-end thread-guiding clip, a far-end thread-guiding clip, a trapezoidal opening and a tainted blood tank cover plate.

The invention discloses a medicine for preventing and treating restenosis after coronary artery stent implantation and a preparation method thereof, which comprises the following raw materials in parts by weight: 800-1200 parts of tanshinone, 200-300 parts of hirudin, 20-30 parts of borneol, 6-9 parts of muscone are made into 1000 parts. The invention has the characteristics of good curative effect, no toxic and side effects, can reduce the incidence of restenosis after coronary artery stent implantation, obviously improve the clinical symptoms of patients, reduce the long-term thrombosis risk of patients, and the like, and has remarkable clinical curative effect. It provides a new option for preventing restenosis (ISR) after coronary stent implantation.

The invention relates to an extension catheter for coronary stent implantation operation. The extension catheter comprises a catheter and a guide wire, wherein the catheter is connected with the guide wire, the catheter comprises a catheter head end, a catheter body and a catheter tail end, one end of the catheter body is connected with the catheter head end, the other end of the catheter body is connected with the catheter tail end, and the surface of the catheter body is provided with micropore structures. When the extension catheter enters a narrow section of a blood vessel to cause blood vessel blockage, the micropore structures can enable blood to circulate, and pain and uncomfortable symptoms of a patient are relieved; the micropore structures are elliptical, so that the scratch to the blood vessel can be reduced, and the injury to patients can be reduced; the position, 3-5 centimeters away from the guide wire, of the catheter is not provided with the micropore structures, and smooth conveying of the extension catheter can be guaranteed; a head hose is arranged, the smooth head can enable the operation process to be safer, the probability of scratching the blood vessel is reduced, and the occurrence of vascular complications is reduced; and the condition of the catheter can be clearly observed through X-ray fluoroscopy in the radiography process through a marking belt, and therefore, the operation can be conveniently performed.

The invention discloses a new material and preparation method of a coronary stent. The main material of the stent is synthesized from titanium, cobalt, magnesium, nickel and iron, and the adsorption material is composed of sterile cotton and the polyhydroxyalkanoate. Asparagus leaves, Rhododendron azalea, staghorn glue, forsythia, Prunella vulgaris, Corydalis, cicada slough, Lismodium, cat's claw, geranium, pinellia, honeysuckle, Angelica dahurica, gardenia, scutellaria baicalensis, and red peony make up the adsorption drug material , compared with the prior art, the present invention adopts various alloys, which can improve the setting ability of the coronary stent and keep it without deformation. The effect has the value of popularization and application.